Amedeo Smart

Free Medical Literature Service


 

Amedeo

HIV Infection

  Free Subscription

Articles published in
Lancet
    January 2018
  1. LLIBRE JM, Hung CC, Brinson C, Castelli F, et al
    Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
    Lancet. 2018 Jan 5. pii: S0140-6736(17)33095.
    >> Share

  2. BICCARD BM, Madiba TE, Kluyts HL, Munlemvo DM, et al
    Perioperative patient outcomes in the African Surgical Outcomes Study: a 7-day prospective observational cohort study.
    Lancet. 2018 Jan 3. pii: S0140-6736(18)30001.
    >> Share

    December 2017
  3. BERNARDO EL, Fuente-Soro L, Lopez-Varela E, Naniche D, et al
    Anonymity in HIV testing: implications for public health.
    Lancet. 2017;390:2546.
    >> Share

    October 2017
  4. LAMONTAGNE F, Fowler RA, Adhikari NK, Murthy S, et al
    Evidence-based guidelines for supportive care of patients with Ebola virus disease.
    Lancet. 2017 Oct 17. pii: S0140-6736(17)31795.
    >> Share

  5. IYER JK, Mendelson M
    Can the Antimicrobial Resistance Benchmark blaze a new trail?
    Lancet. 2017 Oct 13. pii: S0140-6736(17)32670.
    >> Share

    September 2017
  6. POKROVSKY V
    Tuberculosis and HIV/AIDS: the alien and the predator.
    Lancet. 2017;390:1618-1619.
    >> Share

  7. KAZATCHKINE MD
    Health in the Soviet Union and in the post-Soviet space: from utopia to collapse and arduous recovery.
    Lancet. 2017;390:1611-1612.
    >> Share


  8. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016.
    Lancet. 2017;390:1151-1210.
    >> Share


  9. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: a systematic analysis for the Global Burden of Disease Study 2016.
    Lancet. 2017;390:1084-1150.
    >> Share

    August 2017
  10. SAX PE, Pozniak A, Montes ML, Koenig E, et al
    Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-infer
    Lancet. 2017 Aug 31. pii: S0140-6736(17)32340.
    >> Share

  11. BOFFITO M, Venter F
    The triumph of HIV treatment: another new antiretroviral.
    Lancet. 2017 Aug 31. pii: S0140-6736(17)32297.
    >> Share

  12. GALLANT J, Lazzarin A, Mills A, Orkin C, et al
    Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
    Lancet. 2017 Aug 31. pii: S0140-6736(17)32299.
    >> Share

  13. GREEN A
    President of Zambia declares HIV testing mandatory.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32295.
    >> Share

  14. THE LANCET
    Losing the fight against HIV in the Philippines.
    Lancet. 2017;390:626.
    >> Share

    July 2017
  15. KARIM SSA, Karim QA, Abimiku A, Bekker LG, et al
    Closing the NIH Fogarty Center threatens US and global health.
    Lancet. 2017;390:451.
    >> Share

  16. HODSON N, Bewley S
    Nelly Mugo and the response to HIV: more than just PrEP advocacy.
    Lancet. 2017;390:358.
    >> Share

  17. GREEN A
    The HIV response in Ukraine: at a crossroads.
    Lancet. 2017;390:347-348.
    >> Share

  18. BEYRER C, Das P, Horton R, Ryan O, et al
    The International AIDS Society-Lancet Commission on the future of the HIV response and global health.
    Lancet. 2017;390:344-345.
    >> Share

  19. GRANICH R, Williams B, Montaner J, Zuniga JM, et al
    90-90-90 and ending AIDS: necessary and feasible.
    Lancet. 2017;390:341-343.
    >> Share

  20. THE LANCET
    The global HIV/AIDS epidemic-progress and challenges.
    Lancet. 2017;390:333.
    >> Share

  21. BOYD MA, Cooper DA
    Long-acting injectable ART: next revolution in HIV?
    Lancet. 2017 Jul 21. pii: S0140-6736(17)31962.
    >> Share

  22. MARGOLIS DA, Gonzalez-Garcia J, Stellbrink HJ, Eron JJ, et al
    Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
    Lancet. 2017 Jul 21. pii: S0140-6736(17)31917.
    >> Share

    March 2017
  23. DANIELS JP
    Venezuela's economic crisis hampers HIV/AIDS treatment.
    Lancet. 2017;389:1088-1089.
    >> Share

  24. HUFFMAN MD, Xavier D, Perel P
    Uses of polypills for cardiovascular disease and evidence to date.
    Lancet. 2017;389:1055-1065.
    >> Share

  25. MENDENHALL E, Kohrt BA, Norris SA, Ndetei D, et al
    Non-communicable disease syndemics: poverty, depression, and diabetes among low-income populations.
    Lancet. 2017;389:951-963.
    >> Share

  26. MOHAMMADI D
    Growing older with HIV in the UK.
    Lancet. 2017;389:894-895.
    >> Share

    February 2017
  27. DOWNS JA, Mwakisole AH, Chandika AB, Lugoba S, et al
    Educating religious leaders to promote uptake of male circumcision in Tanzania: a cluster randomised trial.
    Lancet. 2017 Feb 14. pii: S0140-6736(16)32055.
    >> Share

    January 2017
  28. CLINTON C, Sridhar D
    Who pays for cooperation in global health? A comparative analysis of WHO, the World Bank, the Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria, and Gavi, the Vaccine Alliance.
    Lancet. 2017 Jan 27. pii: S0140-6736(16)32402.
    >> Share

  29. SHIELS MS, Chernyavskiy P, Anderson WF, Best AF, et al
    Trends in premature mortality in the USA by sex, race, and ethnicity from 1999 to 2014: an analysis of death certificate data.
    Lancet. 2017 Jan 25. pii: S0140-6736(17)30187.
    >> Share

  30. VAN DER REE MH, de Vree JM, Stelma F, Willemse S, et al
    Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial.
    Lancet. 2017 Jan 10. pii: S0140-6736(16)31715.
    >> Share

    December 2016
  31. ZHU FC, Wurie AH, Hou LH, Liang Q, et al
    Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2016 Dec 22. pii: S0140-6736(16)32617.
    >> Share

  32. HOOK EW RD
    Syphilis.
    Lancet. 2016 Dec 16. pii: S0140-6736(16)32411.
    >> Share

    November 2016
  33. DAS P
    Deborah L Birx: on a mission to end the HIV/AIDS epidemic.
    Lancet. 2016;388:2583.
    >> Share

  34. KIRBY T
    Targeting HIV prevention to young women in Africa.
    Lancet. 2016;388:2579.
    >> Share

  35. KIRBY T
    David Cooper: Australia's fighter against HIV and discrimination.
    Lancet. 2016;388:2469.
    >> Share

  36. YANG YT, Wiley E, Duvivier RJ
    US policy on blood donation by men who have sex with men.
    Lancet. 2016;388:2236-2237.
    >> Share

    October 2016
  37. HONORE JG, Balan JG, Thimothe G, Diallo J, et al
    Instability adversely affects HIV care in Haiti.
    Lancet. 2016;388:1877.
    >> Share

  38. GREEN A
    NIH project focuses on integration of HIV and NCD care.
    Lancet. 2016;388:1869.
    >> Share


  39. Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.
    Lancet. 2016;388:1775-1812.
    >> Share


  40. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.
    Lancet. 2016;388:1545-1602.
    >> Share


  41. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015.
    Lancet. 2016;388:1459-1544.
    >> Share

  42. QIN Y, Liu F, Tang W, Tang S, et al
    HIV self-testing among high-risk men who have sex with men in China: a cross-sectional study.
    Lancet. 2016;388 Suppl 1:S76.
    >> Share

  43. MAO J, Tang W, Liu C, Wong NS, et al
    Sex tourism among Chinese men who have sex with men: a cross-sectional observational study.
    Lancet. 2016;388 Suppl 1:S75.
    >> Share

  44. TANG S, Tang W, Meyers K, Chan P, et al
    HIV and syphilis among men who have sex with men and transgender individuals in China: a scoping review.
    Lancet. 2016;388 Suppl 1:S74.
    >> Share

  45. TANG W, Mao J, Liu C, Mollan K, et al
    Crowdsourcing health communication about condom use in men who have sex with men in China: a randomised controlled trial.
    Lancet. 2016;388 Suppl 1:S73.
    >> Share

  46. ZHAO P, Tang S, Wang C, Zhang Y, et al
    Recreational drug use among Chinese MSM: results from a national-wide cross-sectional study.
    Lancet. 2016;388 Suppl 1:S69.
    >> Share

  47. TANG W, Mao J, Tang S, Liu C, et al
    Disclosure of sexual orientation in men who have sex with men in China: a cross-sectional survey.
    Lancet. 2016;388 Suppl 1:S68.
    >> Share

  48. SMITH MK, Miller WC, Liu H, Ning C, et al
    Effects of patient load and travel distance on HIV transmission in a cohort of serodiscordant couples in rural China: a longitudinal analysis.
    Lancet. 2016;388 Suppl 1:S65.
    >> Share

  49. WONG NS, Wong KH, Tsang OT, Lee MP, et al
    HIV testing campaigns and treatment interventions for control of epidemic HIV growth among heterosexuals: a mathematical modelling study.
    Lancet. 2016;388 Suppl 1:S49.
    >> Share

  50. KWAN TH, Poon CM, Wong KH, Lee SS, et al
    Effects of HIV diagnosis and enrolment in care on transmission risk of HIV-infected men who have sex with men in Hong Kong: a cross-sectional study.
    Lancet. 2016;388 Suppl 1:S48.
    >> Share

  51. NING C, Smith KM, McCann CD, Hu F, et al
    Mortality and retention in hospital-based and CDC-based antiretroviral service delivery in people living with HIV in the Guangdong Province, China: a prospective cohort study.
    Lancet. 2016;388 Suppl 1:S26.
    >> Share

  52. WONG WC, Jiang S, Ong J, Peng M, et al
    Availability and use of primary care facilities in China: a nationwide representative survey.
    Lancet. 2016;388 Suppl 1:S18.
    >> Share

    September 2016
  53. HADLAND SE, Wood E, Levy S
    How the paediatric workforce can address the opioid crisis.
    Lancet. 2016;388:1260-1.
    >> Share


  54. Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015.
    Lancet. 2016 Sep 19. pii: S0140-6736(16)31467.
    >> Share

  55. PAN SW, Li D, Carpiano RM, Spittal PM, et al
    Ethnicity and HIV epidemiology research in China.
    Lancet. 2016;388:1052-3.
    >> Share

  56. PIROTH L, Rabaud C, Rey D, Schmit JL, et al
    Hepatitis C: the path towards effective universal therapy.
    Lancet. 2016;388:1051-2.
    >> Share

    August 2016
  57. CLARK F
    Gaps remain in Russia's response to HIV/AIDS.
    Lancet. 2016;388:857-8.
    >> Share

  58. PERSAD GC, Emanuel EJ
    The ethics of expanding access to cheaper, less effective treatments.
    Lancet. 2016;388:932-4.
    >> Share

  59. POKU NK
    UN political declaration on HIV and AIDS: where to begin?
    Lancet. 2016;388:743-744.
    >> Share


  60. NHS England: preparing for PrEP.
    Lancet. 2016;388:634.
    >> Share


  61. Reassessing blood donation by men who have sex with men.
    Lancet. 2016;388:534.
    >> Share

  62. KROIDL I, Saathof E, Maganga L, Makunde WH, et al
    Effect of Wuchereria bancrofti infection on HIV incidence in southwest Tanzania: a prospective cohort study.
    Lancet. 2016 Aug 2. pii: S0140-6736(16)31252.
    >> Share

  63. DOWNS JA, Fitzgerald DW
    No more neglect of helminths and HIV.
    Lancet. 2016 Aug 2. pii: S0140-6736(16)31253.
    >> Share

    July 2016
  64. RUBIN R
    US prisons missing opportunities to tackle HIV in inmates.
    Lancet. 2016 Jul 14. pii: S0140-6736(16)31078.
    >> Share

  65. RUBENSTEIN LS, Amon JJ, McLemore M, Eba P, et al
    HIV, prisoners, and human rights.
    Lancet. 2016 Jul 14. pii: S0140-6736(16)30663.
    >> Share

  66. KAMARULZAMAN A, Reid SE, Schwitters A, Wiessing L, et al
    Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners.
    Lancet. 2016 Jul 14. pii: S0140-6736(16)30769.
    >> Share

  67. ALTICE FL, Azbel L, Stone J, Brooks-Pollock E, et al
    The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia.
    Lancet. 2016 Jul 14. pii: S0140-6736(16)30856.
    >> Share

  68. DOLAN K, Wirtz AL, Moazen B, Ndeffo-Mbah M, et al
    Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees.
    Lancet. 2016 Jul 14. pii: S0140-6736(16)30466.
    >> Share

  69. RICH JD, Beckwith CG, Macmadu A, Marshall BD, et al
    Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis.
    Lancet. 2016 Jul 14. pii: S0140-6736(16)30379.
    >> Share

  70. SHRAGE L
    African Americans, HIV, and mass incarceration.
    Lancet. 2016 Jul 14. pii: S0140-6736(16)30830.
    >> Share

  71. DAS P, Horton R
    On both sides of the prison walls-prisoners and HIV.
    Lancet. 2016 Jul 14. pii: S0140-6736(16)30892.
    >> Share

  72. TELISINGHE L, Charalambous S, Topp SM, Herce ME, et al
    HIV and tuberculosis in prisons in sub-Saharan Africa.
    Lancet. 2016 Jul 14. pii: S0140-6736(16)30578.
    >> Share

  73. BEYRER C, Kamarulzaman A, McKee M
    Prisoners, prisons, and HIV: time for reform.
    Lancet. 2016 Jul 14. pii: S0140-6736(16)30829.
    >> Share

  74. BEYRER C, Baral SD, Collins C, Richardson ET, et al
    The global response to HIV in men who have sex with men.
    Lancet. 2016;388:198-206.
    >> Share

  75. WIKTOR SZ, Hutin YJ
    The global burden of viral hepatitis: better estimates to guide hepatitis elimination efforts.
    Lancet. 2016 Jul 6. pii: S0140-6736(16)31018.
    >> Share

    June 2016
  76. WYLIE K, Knudson G, Khan SI, Bonierbale M, et al
    Serving transgender people: clinical care considerations and service delivery models in transgender health.
    Lancet. 2016 Jun 16. pii: S0140-6736(16)00682.
    >> Share

  77. REISNER SL, Poteat T, Keatley J, Cabral M, et al
    Global health burden and needs of transgender populations: a review.
    Lancet. 2016 Jun 16. pii: S0140-6736(16)00684.
    >> Share

  78. GUISE A
    Next generation of comprehensive HIV prevention.
    Lancet. 2016;387:2377-8.
    >> Share

  79. SIDIBE M, Singh PK
    Thailand eliminates mother-to-child transmission of HIV and syphilis.
    Lancet. 2016 Jun 9. pii: S0140-6736(16)30787.
    >> Share

    May 2016
  80. LOMBARD C, Cousens S, Tylleskar T, Van de Perre P, et al
    Trial size, HIV pre-exposure prophylaxis, and breastfeeding - Authors' reply.
    Lancet. 2016;387:2091.
    >> Share

  81. BIRD SM
    Trial size, HIV pre-exposure prophylaxis, and breastfeeding.
    Lancet. 2016;387:2090-1.
    >> Share

  82. SHAPIRO R, Dryden-Peterson S, Powis K, Zash R, et al
    Hidden in plain sight: HIV, antiretrovirals, and stillbirths.
    Lancet. 2016;387:1994-1995.
    >> Share

  83. MOKDAD AH, Forouzanfar MH, Daoud F, Mokdad AA, et al
    Global burden of diseases, injuries, and risk factors for young people's health during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.
    Lancet. 2016 May 9. pii: S0140-6736(16)00648.
    >> Share

    April 2016
  84. ADAMS P
    Cryptococcal meningitis: a blind spot in curbing AIDS.
    Lancet. 2016;387:1605-6.
    >> Share

  85. SNYDER A
    Willard Cates, Jr.
    Lancet. 2016;387:1506.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016